Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Blood deficiency" is not the name of any recognized therapeutic target, receptor, enzyme, transporter, or gene. Instead, it is an outdated or non-specific term most commonly referring to anemia, which is defined as having too few red blood cells or too little hemoglobin in the blood. Anemia itself is a clinical syndrome with many possible causes—including nutritional deficiencies (iron, vitamin B12), genetic disorders (thalassemia), chronic diseases (kidney disease), and more—but it does not refer to any single molecule or druggable biological entity[1][3][5]. Therefore, "blood deficiency" should not be considered as an individual therapeutic target.
Not applicable as "blood deficiency" is not a molecular target. Mechanisms relate to correcting underlying causes of anemia—e.g., iron supplementation increases hemoglobin synthesis.[1]
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood deficiency.